Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 762178, 11 pages
http://dx.doi.org/10.1155/2015/762178
Clinical Study

Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines

1Research Unit in Biomedicine and Translational Oncology, Vall d’Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
2Department of Urology, Vall d’Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
3Departament de Ciències Bàsiques, Universitat Internacional de Catalunya, Josep Trueta s/n, Sant Cugat del Vallès, 08195 Barcelona, Spain
4Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de l’Hospitalet 199, 08907 Barcelona, Spain
5Department of Pathology, Vall d’Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain

Received 5 June 2014; Accepted 18 September 2014

Academic Editor: Jeremy Clark

Copyright © 2015 M. Olivan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Center, A. Jemal, J. Lortet-Tieulent et al., “International variation in prostate cancer incidence and mortality rates,” European Urology, vol. 61, no. 6, pp. 1079–1092, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2013,” CA Cancer Journal for Clinicians, vol. 63, no. 1, pp. 11–30, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. W. Hsing and S. S. Devesa, “Trends and patterns of prostate cancer: what do they suggest?” Epidemiologic Reviews, vol. 23, no. 1, pp. 3–13, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. P. C. Albertsen, “Screening for prostate cancer is neither appropriate nor cost-effective,” Urologic Clinics of North America, vol. 23, no. 4, pp. 521–530, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-A. Thomas II, L. Gerber, L. L. Bañez et al., “Prostate cancer risk in men with baseline history of coronary artery disease: results from the reduce study,” Cancer Epidemiology Biomarkers and Prevention, vol. 21, no. 4, pp. 576–581, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. J. Gonyeau and D. W. Yuen, “A clinical review of statins and cancer: helpful or harmful?” Pharmacotherapy, vol. 30, no. 2, pp. 177–194, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. P. McGettigan and D. Henry, “Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2,” Journal of the American Medical Association, vol. 296, no. 13, pp. 1633–1644, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. S. M. Mahmud, E. L. Franco, and A. G. Aprikian, “Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis,” International Journal of Cancer, vol. 127, no. 7, pp. 1680–1691, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. S. Bonovas, K. Filioussi, and N. M. Sitaras, “Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies,” International Journal of Cancer, vol. 123, no. 4, pp. 899–904, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. Mann, K. Reynolds, D. Smith, and P. Muntner, “Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines,” Annals of Pharmacotherapy, vol. 42, no. 9, pp. 1208–1215, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. K. Jain and P. M. Ridker, “Anti-inflammatory effects of statins: clinical evidence and basic mechanisms,” Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 977–987, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Carlberg, A. Dricu, H. Blegen et al., “Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth,” Journal of Biological Chemistry, vol. 271, no. 29, pp. 17453–17462, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. W. W.-L. Wong, J. Dimitroulakos, M. D. Minden, and L. Z. Penn, “HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis,” Leukemia, vol. 16, no. 4, pp. 508–519, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Dulak and A. Józkowicz, “Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy,” Current Cancer Drug Targets, vol. 5, no. 8, pp. 579–594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. T. J. Murtola, T. Visakorpi, J. Lahtela, H. Syvälä, and T. L. J. Tammela, “Statins and prostate cancer prevention: where we are now, and future directions,” Nature Clinical Practice Urology, vol. 5, no. 7, pp. 376–387, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. R. E. Harris, J. Beebe-Donk, H. Doss, and D. Burr Doss, “Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review),” Oncology Reports, vol. 13, no. 4, pp. 559–583, 2005. View at Google Scholar · View at Scopus
  17. L. A. Habel, W. Zhao, and J. L. Stanford, “Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US,” Cancer Causes and Control, vol. 13, no. 5, pp. 427–434, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. G. Rodríguez and A. González-Pérez, “Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 13, no. 4, pp. 649–653, 2004. View at Google Scholar · View at Scopus
  19. E. J. Jacobs, C. Rodriguez, A. M. Mondul et al., “A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence,” Journal of the National Cancer Institute, vol. 97, no. 13, pp. 975–980, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. K. Dasgupta, D. Di Cesar, J. Ghosn, R. Rajan, S. Mahmud, and E. Rahme, “Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence,” Cancer Journal, vol. 12, no. 2, pp. 130–135, 2006. View at Google Scholar · View at Scopus
  21. A. I. Neugut, D. J. Rosenberg, H. Ahsan et al., “Association between coronary heart disease and cancers of the breast, prostate, and colon,” Cancer Epidemiology Biomarkers & Prevention, vol. 7, no. 10, pp. 869–873, 1998. View at Google Scholar · View at Scopus
  22. C. Bosetti, R. Talamini, E. Negri, S. Franceschi, M. Montella, and C. La Vecchia, “Aspirin and the risk of prostate cancer,” European Journal of Cancer Prevention, vol. 15, no. 1, pp. 43–45, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. F. Leitzmann, M. J. Stampfer, J. Ma et al., “Aspirin use in relation to risk of prostate cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 10 I, pp. 1108–1111, 2002. View at Google Scholar · View at Scopus
  24. C. Siemes, L. E. Visser, J. W. W. Coebergh, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “Protective effect of NSAIDs on cancer and influence of COX-2 C-765G genotype,” Current Cancer Drug Targets, vol. 8, no. 8, pp. 753–764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. M. Rothwell, M. Wilson, J. F. Price, J. F. F. Belch, T. W. Meade, and Z. Mehta, “Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials,” The Lancet, vol. 379, no. 9826, pp. 1591–1601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Algotar, P. A. Thompson, J. Ranger-Moore et al., “Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity,” Prostate, vol. 70, no. 8, pp. 883–888, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. M. Remzi, Y. K. Fong, M. Dobrovits et al., “The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume,” Journal of Urology, vol. 174, part 1, no. 4, pp. 1256–1261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. T. J. Murtola, P. Pennanen, H. Syvälä, M. Bläuer, T. Ylikomi, and T. L. J. Tammela, “Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations,” Prostate, vol. 69, no. 9, pp. 1017–1023, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. K. K. Wu, “Aspirin and salicylate: an old remedy with a new twist,” Circulation, vol. 102, no. 17, pp. 2022–2023, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. C. M. Beaver, “The effect of culture conditions on colony morphology and proliferative capacity in human prostate cancer cell lines,” Cell Biology and Toxicology, vol. 28, no. 5, pp. 291–301, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. T. Nauseef and M. D. Henry, “Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?” Nature Reviews Urology, vol. 8, no. 8, pp. 428–439, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. N. Tan, E. A. Klein, J. Li, A. S. Moussa, and J. S. Jones, “Statin use and risk of prostate cancer in a population of men who underwent biopsy,” Journal of Urology, vol. 186, no. 1, pp. 86–90, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. T. J. Murtola, T. L. J. Tammela, L. Määttänen et al., “Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial,” International Journal of Cancer, vol. 127, no. 7, pp. 1650–1659, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. L. Perron, I. Bairati, L. Moore, and F. Meyer, “Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer,” International Journal of Cancer, vol. 106, no. 3, pp. 409–415, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. E. A. Platz, S. Rohrmann, J. D. Pearson et al., “Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging,” Cancer Epidemiology Biomarkers & Prevention, vol. 14, no. 2, pp. 390–396, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. X. Liu, S. J. Plummer, N. L. Nock, G. Casey, and J. S. Witte, “Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha,” The American Journal of Epidemiology, vol. 164, no. 10, pp. 984–989, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. C. Bosetti, V. Rosato, S. Gallus, and C. la Vecchia, “Aspirin and urologic cancer risk: an update,” Nature Reviews Urology, vol. 9, no. 2, pp. 102–110, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, and C. La Vecchia, “Aspirin and cancer risk: a quantitative review to 2011,” Annals of Oncology, vol. 23, no. 6, pp. 1403–1415, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. T. M. Brasky, C. M. Velicer, A. R. Kristal, U. Peters, J. D. Potter, and E. White, “Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 12, pp. 3185–3188, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. P. K. Dhillon, S. A. Kenfield, M. J. Stampfer, and E. L. Giovannucci, “Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988–2006,” International Journal of Cancer, vol. 128, no. 10, pp. 2444–2452, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. A. Brookhart, A. R. Patrick, C. Dormuth et al., “Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect,” American Journal of Epidemiology, vol. 166, no. 3, pp. 348–354, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. C. D. Berg, G. L. Andriole, E. D. Crawford et al., “Mortality results from a randomized prostate-cancer screening trial,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1310–1319, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. F. H. Schröder, J. Hugosson, M. J. Roobol et al., “Screening and prostate-cancer mortality in a randomized european study,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1320–1328, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. M. Brown, C. Hart, T. Tawadros et al., “The differential effects of statins on the metastatic behaviour of prostate cancer,” British Journal of Cancer, vol. 106, no. 10, pp. 1689–1696, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. Hoque, H. Chen, and X.-C. Xu, “Statin induces apoptosis and cell growth arrest in prostate cancer cells,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 1, pp. 88–94, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. T. J. Murtola, H. Syvälä, P. Pennanen et al., “Comparative effects of high and low-dose simvastatin on prostate epithelial cells: the role of LDL,” European Journal of Pharmacology, vol. 673, no. 1–3, pp. 96–100, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. M. O'Shaughnessy, B. Konety, and C. Warlick, “Prostate cancer screening: issues and controversies,” Minnesota Medicine, vol. 93, no. 8, pp. 39–44, 2010. View at Google Scholar · View at Scopus
  48. C. L. Amling, M. L. Blute, E. J. Bergstralh, T. M. Seay, J. Slezak, and H. Zincke, “Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years,” Journal of Urology, vol. 164, no. 1, pp. 101–105, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Mitchell, K. B. Svenson, W. M. Longmate et al., “Suppression of integrin α3β1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells,” Cancer Research, vol. 70, no. 15, pp. 6359–6367, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. N. E. Ramirez, Z. Zhang, A. Madamanchi et al., “The α2β1 integrin is a metastasis suppressor in mouse models and human cancer,” The Journal of Clinical Investigation, vol. 121, no. 1, pp. 226–237, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. C. L. Hall, C. W. Dubyk, T. A. Riesenberger, D. Shein, E. T. Keller, and K. L. Van Golen, “Type I collagen receptor (α2β1) signaling promotes prostate cancer invasion through RhoC GTPase,” Neoplasia, vol. 10, no. 8, pp. 797–803, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Van Slambrouck, A. R. Jenkins, A. E. Romero, and W. F. A. Steelant, “Reorganization of the integrin α2 subunit controls cell adhesion and cancer cell invasion in prostate cancer,” International Journal of Oncology, vol. 34, no. 6, pp. 1717–1726, 2009. View at Publisher · View at Google Scholar · View at Scopus